EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Janus Kinase Inhibitors for Vitiligo Treatment

Wanlin Wang, Yue Liao, Ruizhi Zhang, Jijun Huang, Jiamin Liu, Xiaokang Shan, Xiaojing Gao, Jin Bu iD, Yaping Tang, Erxia Shen

Drug Research · 01.03.2026 · 76 (02/03) · 57-64

DOI: 10.1055/a-2784-6722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Research, erschienen am 01.03.2026. Verfasst von Wanlin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sino-French Hoffmann Institute, School of Basic Medical Sciences, The Second Affiliated Hospital of Guangzhou Medical University, State Key Laborator…. Hauptthemen laut MEDLINE: Vitiligo, Janus Kinase Inhibitors, Janus Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitiligo is a cutaneous autoimmune disease characterized by the destruction of epidermal melanocytes leading to white patches with a global prevalence of about 0.5–2%, and patients’ quality of life are greatly affected by the change in appearance and social discrimination caused by the disease. Most of the key cytokines in the pathogenesis of vitiligo act through the Janus kinase/signal transducer and activator of transcription signaling pathway, which is an effective therapeutic target. The first generation Janus kinase inhibitors, i.e., tofacitinib and ruxolitinib, inhibit a variety of Janus kinases, whereas the new generation Janus kinase inhibitors, such as ritlecitinib and upadacitinib, exhibit inhibitory effects only on specific Janus kinases; they are therefore selective as well as safer and more effective. In this review, we aim to provide an up-to-date view of vitiligo pathogenesis at the cellular, molecular, and genetic levels and further to elucidate the relationship between Janus kinase/signal transducer and activator of transcription signaling pathway components and vitiligo. Finally, we summarize currently market-approved and preclinical Janus kinase inhibitors, highlighting the latest advances in their clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoJanus Kinase InhibitorsJanus KinasesHumansSignal TransductionAnimalsPyrimidinesPyrazolesNitrilesQuality of LifePiperidines

Substanzen

Janus Kinase InhibitorsJanus KinasestofacitinibPyrimidinesruxolitinibPyrazolesNitrilesPiperidines

Autor:innen und Institutionen

  • Sino-French Hoffmann Institute, School of Basic Medical Sciences, The Second Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Aller…
  • Department of Emergency Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
  • Department of Dermatology, Guangzhou hospital of Dermatology, Guangzhou, China, Guangzhou, China.
  • Institute of Dermatology, Guangzhou Medical University, Guangzhou, China, Guangzhou, China.

ORCID-Profile: Jin Bu

Zitieren

APA

Wang, W., Liao, Y., Zhang, R., Huang, J., Liu, J., Shan, X., Gao, X., Bu, J., Tang, Y., & Shen, E. (2026). Advances in Janus Kinase Inhibitors for Vitiligo Treatment. Drug Research, 76(02/03), 57-64. https://doi.org/10.1055/a-2784-6722

Vancouver

Wang W, Liao Y, Zhang R, Huang J, Liu J, Shan X, et al. Advances in Janus Kinase Inhibitors for Vitiligo Treatment. Drug Research. 2026;76(02/03):57-64. doi:10.1055/a-2784-6722

BibTeX
@article{Wang2026,
  author = {Wang, Wanlin and Liao, Yue and Zhang, Ruizhi and Huang, Jijun and Liu, Jiamin and Shan, Xiaokang and Gao, Xiaojing and Bu, Jin and Tang, Yaping and Shen, Erxia},
  title = {Advances in Janus Kinase Inhibitors for Vitiligo Treatment},
  journal = {Drug Research},
  year = {2026},
  volume = {76},
  number = {02/03},
  pages = {57--64},
  doi = {10.1055/a-2784-6722}
}
Kostenlos starten →